Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un ensayo de fase II de estimulación eléctrica superficial para la incontinencia urinaria en hombres tratados por cáncer de próstata

7 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Background:

Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.

Objective:

To see if the Elidah device can reduce urinary incontinence after prostate treatment.

Eligibility:

Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.

Design:

Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.

The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.

Participants will be given an Elidah device and taught how to use it at home.

They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.

Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.

Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.

Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.

Participants will complete 15-minute questionnaires.

Descripción general del estudio

Descripción detallada

Background:

  • Urinary incontinence is a common side effect of prostate cancer therapy that can negatively impact the quality of life.
  • Standard treatment includes an initial course of pelvic floor muscle exercises followed by surgical therapy if urinary incontinence persists.
  • Although pelvic floor muscle exercises can be successful in reducing urinary incontinence, compliance with exercises is poor.
  • The Elitone (registered trademark) device was recently cleared by the Food and Drug Administration (FDA) for use in women with stress urinary incontinence. This device provides a surface electrical muscle stimulation device designed to contract the pelvic floor muscles and has been shown to reduce incontinence in women using the product.
  • Recently, the electrode component (GelPad) of the device has been adapted for use in men by the manufacturing company, Elidah. The male version of the device is named the Elidah device.

Objective:

-To describe the efficacy of the Elidah device on male urinary incontinence

Eligibility:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities), or on sneezing or coughing;
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.

Design:

  • This is a phase II trial testing the efficacy of the Elidah device in people treated for prostate cancer with stress and/or urge urinary incontinence.
  • Prior to treatment, participants will undergo baseline assessments including 24-hour pad weight testing and questionnaires relating to incontinence and quality of life.
  • Participants will self-administer the Elidah device treatment for 20 minutes per day, 5 days per week during a 6-week period in the at-home environment. Participants will maintain a Daily Log to record usage of the Elidah device, urinary leaks, and use of pads during each week of treatment.
  • Following 6 weeks of therapy, participants will undergo re-evaluation of symptoms and urinary incontinence via questionnaires and testing with the 24-hour pad weight test.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

41

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Deborah E Citrin, M.D.
  • Número de teléfono: (240) 760-6206
  • Correo electrónico: citrind@mail.nih.gov

Copia de seguridad de contactos de estudio

  • Nombre: Debbie-Ann N Nathan, R.N.
  • Número de teléfono: (240) 858-3103
  • Correo electrónico: dnathan@mail.nih.gov

Ubicaciones de estudio

    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • Reclutamiento
        • National Institutes of Health Clinical Center
        • Contacto:
          • National Cancer Institute Referral Office
          • Número de teléfono: 888-624-1937

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 120 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

  • INCLUSION CRITERIA:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
  • Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.

  • Participants must be able to read and write in English.

  • Age >= 18 years.

  • Eastern Cooperative Oncology Group (ECOG) performance status <= 2.

  • Ability to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Change of therapy for prostate cancer planned during the study intervention.
  • History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.
  • Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (>= 4 UTIs within the 12 months prior to the study treatment initiation).
  • History of complete denervation of the pelvic floor.
  • Severe obesity (body mass index [BMI] >35).
  • Pelvic pain/painful bladder syndrome.
  • Metal implant in the abdominal or pelvic area.
  • History of chronic cough with ongoing symptoms
  • An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.
  • History of epilepsy.
  • History of underlying neurologic/neuromuscular disorder that could contribute to urinary incontinence.
  • Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.
  • Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: 1/Elidah Device

Elidah device application.

The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To describe the efficacy of the Elidah device treatment on male urinary incontinence
Periodo de tiempo: Baseline and within 2 weeks after completing treatment

Percent decrease in 24-hour pad weight after treatment with the Elidah device.

Baseline and within 2 weeks after completing treatment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To assess the safety of the Elidah device in men with urinary incontinence
Periodo de tiempo: 3 week visit and end of treatment visit

Frequency of adverse events among treated participants and reporting the results, by maximum grade of event and type of toxicity noted.

3 week visit and end of treatment visit
To assess alternative measures of efficacy of Elidah device on male urinary incontinence and bother
Periodo de tiempo: Baseline and at end of treatment visit

Evaluated by the number of pads and number of leaks before and after treatment. The mean of the percent reduction in the number of pads used per day following treatment will be computed along with 95% confidence intervals.

Baseline and at end of treatment visit
To assess participant-reported outcomes of Elidah device use for male urinary incontinence
Periodo de tiempo: Baseline and at end of treatment visit

The proportion of participants for which the I-QoL score improves by 2.5 points or more following six weeks of Elidah device use will be estimated. 95% confidence intervals for this proportion will be constructed.

Baseline and at end of treatment visit
To assess treatment compliance with the Elidah device
Periodo de tiempo: 3 week visit and end of treatment visit

A test of binomial proportions will be performed to assess whether the treatment noncompliance rate is above the unacceptability threshold.

3 week visit and end of treatment visit

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Deborah E Citrin, M.D., National Cancer Institute (NCI)

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de febrero de 2024

Finalización primaria (Estimado)

1 de diciembre de 2027

Finalización del estudio (Estimado)

1 de marzo de 2028

Fechas de registro del estudio

Enviado por primera vez

1 de diciembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

1 de diciembre de 2023

Publicado por primera vez (Actual)

8 de diciembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

7 de noviembre de 2026

Última verificación

6 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All IPD recorded in the medical record will be shared with intramural investigators upon request.

Marco de tiempo para compartir IPD

Clinical data available during the study and indefinitely.

Criterios de acceso compartido de IPD

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir